SS Innovations' 195 Telesurgeries Signal a New Era in Remote Robotic Care

SS Innovations International's SSi Mantra system has enabled 195 telesurgeries across global markets, demonstrating the commercial viability of remote robotic surgery and the company's expanding global footprint.

Chicago Metrowire Staff
••Healthcare
SS Innovations' 195 Telesurgeries Signal a New Era in Remote Robotic Care

The announcement that SS Innovations International (NASDAQ: SSII) has supported 195 robotic telesurgeries as of September 28, 2026, matters because it moves remote surgery from experimental pilot programs toward routine clinical practice. Telesurgery, in which a surgeon operates on a patient located hundreds or thousands of miles away using a robotic system and high-speed communications links, has long been constrained by latency, reliability, and regulatory hurdles. The SSi Mantra system’s ability to support cardiac procedures and operations across significant geographic distances suggests those barriers are being overcome, with implications for how care is delivered in underserved regions and for the economics of surgical robotics.

The scale of SS Innovations’ deployment reinforces that implication. The company reported a 45% increase in its installed base to 244 systems across 12 countries, with cumulative surgical procedures reaching 14,503 and approximately 1,500 physicians trained on the platform. That installed base and training pipeline matter because they create the clinical familiarity and data volume needed to validate telesurgery across specialties and geographies. Recent international expansion includes new robotic cardiac surgery programs in Colombia, Sri Lanka, and India, regions where access to specialized cardiac surgeons can be limited. For investors, the metrics provide a tangible adoption curve in a market where SS Innovations is positioning its technology as affordable and accessible; more detail is available via the company’s full article and its SSII newsroom.

The strategic importance extends to regulatory pathways. SS Innovations is pursuing U.S. FDA clearance and European Union CE marking to support entry into additional markets. Those approvals would matter because they would open access to two of the world’s largest and most regulated healthcare markets, where reimbursement and hospital adoption decisions depend on cleared indications. The company’s product range, including the SSi Mantra system and SSi Mudra instruments, is developed with a vision to make robotic surgery affordable and accessible to a larger segment of the global population, according to its SSInnovations.com website.

The news also reflects a broader convergence of surgical robotics and communications technology, a theme tracked by TechMediaWire, a specialized communications platform focused on pioneering technology companies. TechMediaWire operates within the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and editorial syndication to 5,000+ outlets, among other services.

For the medical community, the key implication is that telesurgery could help address surgeon shortages and extend specialized expertise to remote or underserved areas, provided that latency, security, and clinical outcomes continue to be validated. For SS Innovations, the 195 telesurgeries and 244-system installed base represent a proof point that could accelerate hospital adoption as regulatory clearances advance. As the company pursues FDA and CE mark approvals, the coming period will test whether its early global traction translates into broader market access and sustained clinical adoption.

Blockchain Registration

QR Code for Blockchain Registration